



CHIMERIX

October 15, 2015

Chimerix to Webcast Annual Investor Update on October 22, 2015

DURHAM, N.C., Oct. 15, 2015 (GLOBE NEWSWIRE) -- Chimerix, Inc. (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that it will webcast the Company's annual investor update on Oct. 22, 2015, from 4:30 p.m. to 6:30 p.m. ET.

To access the live webcast or archived replay, please visit the Investor Relations section of Chimerix's website at <http://ir.chimerix.com/events.cfm>.

About Chimerix

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (CMX001), a clinical-stage nucleotide analog, CMX157 which was licensed to ContraVir Pharmaceuticals in 2014, and early clinical candidates including CMX669. For further information, please visit Chimerix's website, www.chimerix.com.

CONTACT: Joseph T. Schepers

Executive Director, Investor Relations and Corporate Communications

ir@chimerix.com

919-287-4125

Source: Chimerix, Inc.

News Provided by Acquire Media